Baloxavir Marboxil

USDailyMed:Baloxavir marboxil AU:B3 J05AX25(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl methyl carbonate 1985606-14-1 124081896 DB13997 59718643 505CXM6OHG D11021 DTXSID601027758 Interactive image O=C(OCOC(C(C=C1)=O)=C(N1N([C@@H]2C3=CC=CC=C3SCC4=C(F)C(F)=CC=C24)[C@@]5([H])N6CCOC5)C6=O)OC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1Key:RZVPBGBYGMDSBG-GGAORHGYSA-N Baloxavir marboxil, sold under the brand nameXofluza, is anantiviral medicationused for the treatment ofinfluenza Aandinfluenza B.It was approved for medical use both in Japan and in the United States in 2018,and is takenby mouth.It can reduce the duration of flu symptoms by about 1-2 days in some people, but can also develop selection of resistant mutants that render it ineffectual; however studies noted this was seen mostly in children that were studied.[unreliable medical source?] Baloxavir marboxil was developed as aprodrugstrategy, with its metabolism releasing the active agent, baloxavir acid. Baloxavir acid then functions asenzyme inhibitor, targeting the influenza virus'cap-dependentendonucleaseactivity, used in "cap snatching" by thevirus'polymerasecomplex, a process essential to its life-cycle. The most common side effects of baloxavir marboxil includediarrhea,bronchitis,nausea,sinusitis, andheadache. The USFood and Drug Administrationconsiders baloxavir marboxil to be afirst-in-class medication.